
---
title: Leukaemia - INICET High Yield
markmap:
  colorFreezeLevel: 3
---

# Leukaemia
## AML (Acute Myeloid Leukaemia)
### Classification
- FAB (M0-M7)
  - M1: Myeloblastic w/o maturation
  - M2: Myeloblastic w maturation
  - M3: Promyelocytic (APL)
  - M4: Myelomonocytic
  - M5: Monocytic
  - M6: Erythroleukaemia
  - M7: Megakaryoblastic
- WHO (Genetic basis)
### Diagnosis
- Morphology: Blasts (>20%), Auer rods
- Cytochemistry: MPO+, SBB+, NSE (M4/M5)
- Immunophenotyping: CD13, CD33, CD117, CD34 (variable)
- Cytogenetics/Molecular
  - t(15;17): APL (PML-RARA) - Favorable
  - t(8;21): AML1-ETO - Favorable
  - inv(16)/t(16;16): CBFBMYH11 - Favorable
  - FLT3-ITD: Poor Prognosis
  - NPM1 mutation: Favorable (if FLT3-ITD low/absent)
### Clinical Features
- Fatigue, Pallor, Bleeding, Infection
- Gum hypertrophy (M4/M5)
- Chloroma (Granulocytic sarcoma)
- DIC (M3/APL)
### Treatment
- Induction: Cytarabine + Anthracycline (7+3)
- APL: ATRA + Arsenic Trioxide (ATO)
- Consolidation: Chemo / SCT
### Prognosis: Risk Stratified by Genetics
## ALL (Acute Lymphoblastic Leukaemia)
### Classification
- FAB (L1-L3)
- Immunophenotype (B-ALL, T-ALL)
### Diagnosis
- Morphology: Blasts (>20%) - scant cytoplasm, lymphoid appearance
- Cytochemistry: SBB-, MPO-, PAS+ (L1/L2)
- Immunophenotyping:
  - B-ALL: CD19, CD20, CD22, cCD79a, TdT
  - T-ALL: CD3 (cyto/surface), CD2, CD5, CD7, TdT
- Cytogenetics/Molecular
  - t(12;21): TEL-AML1 - Good Prognosis (Common in children)
  - t(9;22): Ph+ (BCR-ABL) - Poor Prognosis (Common in adults)
  - MLL rearrangements (11q23) - Poor Prognosis (Infants)
  - Hyperdiploidy: Good Prognosis
### Clinical Features
- Children > Adults
- Fatigue, Pallor, Bleeding, Infection
- Bone pain, Lymphadenopathy, Splenomegaly
- CNS involvement (common)
- Mediastinal mass (T-ALL)
### Treatment
- Induction, Consolidation, Maintenance, CNS prophylaxis
### Prognosis: Age, WBC, Cytogenetics
## CML (Chronic Myeloid Leukaemia)
### Pathogenesis: t(9;22) Philadelphia Chromosome
- BCR-ABL fusion gene
### Clinical Features
- Asymptomatic
- Splenomegaly (massive)
- Fatigue, Weight loss, Night sweats (hypermetabolic)
- Increased WBC (myeloid series), Basophilia, Eosinophilia
### Phases
- Chronic Phase
- Accelerated Phase
- Blast Crisis (>20% blasts)
### Diagnosis
- Peripheral Smear: Leukoerythroblastic picture, Basophilia
- Bone Marrow: Hypercellular, increased M:E ratio
- Cytogenetics/FISH/PCR: Detect t(9;22) / BCR-ABL
### Treatment
- Tyrosine Kinase Inhibitors (TKIs): Imatinib, Dasatinib, Nilotinib
- SCT (Selected cases)
### Monitoring: Molecular Response (BCR-ABL transcript levels)
## CLL (Chronic Lymphocytic Leukaemia)
### Pathogenesis: Clonal B cell proliferation
### Clinical Features
- Elderly patients
- Asymptomatic (often)
- Lymphadenopathy, Splenomegaly
- Cytopenias (AIHA, ITP, BM infiltration)
### Diagnosis
- Peripheral Smear: Absolute Lymphocytosis, Smudge cells
- Immunophenotyping: CD5+, CD23+, CD19+, FMC7- (Key markers)
- Bone Marrow (not always req)
- Staging (Rai, Binet)
### Prognosis
- IGHV mutational status (Mutated - Better)
- ZAP-70+, CD38+ (Poor)
- Cytogenetics: del(17p) / TP53 mutation (Poor), del(11q) (Poor), del(13q) (Good)
### Treatment
- Watch & Wait (Early asymptomatic)
- Chemoimmunotherapy (FCR)
- Targeted Agents: BTK inhibitors (Ibrutinib), BCL-2 inhibitors (Venetoclax)
### Complications
- Autoimmune Cytopenias (AIHA, ITP)
- Hypogammaglobulinemia
- Infections
- Richter's transformation (to high-grade lymphoma)
## High Yield Buzzwords
- Auer rods (AML)
- Smudge cells (CLL)
- Philadelphia Chromosome t(9;22) (CML, ALL)
- ATRA (APL)
- TKIs (CML, Ph+ ALL)
- CD10 (CALLA) (B-ALL)
- CD5+CD23+ (CLL)
- DIC (APL)
- Chloroma (AML)
- Gum hypertrophy (AML M4/M5)
- CNS leukaemia (ALL)
- Mediastinal mass (T-ALL)
- Richter's transformation (CLL)
- Blast Crisis (CML)
- Tumour Lysis Syndrome
- Hyperleukocytosis
- IGHV, ZAP-70, del(17p) (CLL Prognosis)
